Literature DB >> 25787197

Randomized Trial of Stents Versus Bypass Surgery for Left Main Coronary Artery Disease: 5-Year Outcomes of the PRECOMBAT Study.

Jung-Min Ahn1, Jae-Hyung Roh1, Young-Hak Kim1, Duk-Woo Park1, Sung-Cheol Yun2, Pil Hyung Lee1, Mineok Chang1, Hyun Woo Park1, Seung-Whan Lee1, Cheol Whan Lee1, Seong-Wook Park1, Suk Jung Choo1, CheolHyun Chung1, JaeWon Lee1, Do-Sun Lim3, Seung-Woon Rha4, Sang-Gon Lee5, Hyeon-Cheol Gwon6, Hyo-Soo Kim7, In-Ho Chae8, Yangsoo Jang9, Myung-Ho Jeong10, Seung-Jea Tahk11, Ki Bae Seung12, Seung-Jung Park13.   

Abstract

BACKGROUND: In a previous randomized trial, we found that percutaneous coronary intervention (PCI) was not inferior to coronary artery bypass grafting (CABG) for the treatment of unprotected left main coronary artery stenosis at 1 year.
OBJECTIVES: This study sought to determine the 5-year outcomes of PCI compared with CABG for the treatment of unprotected left main coronary artery stenosis.
METHODS: We randomly assigned 600 patients with unprotected left main coronary artery stenosis to undergo PCI with a sirolimus-eluting stent (n = 300) or CABG (n = 300). The primary endpoint was a major adverse cardiac or cerebrovascular event (MACCE: a composite of death from any cause, myocardial infarction, stroke, or ischemia-driven target vessel revascularization) and compared on an intention-to-treat basis.
RESULTS: At 5 years, MACCE occurred in 52 patients in the PCI group and 42 patients in the CABG group (cumulative event rates of 17.5% and 14.3%, respectively; hazard ratio [HR]: 1.27; 95% confidence interval [CI]: 0.84 to 1.90; p = 0.26). The 2 groups did not differ significantly in terms of death from any cause, myocardial infarction, or stroke as well as their composite (8.4% and 9.6%; HR, 0.89; 95% CI, 0.52 to 1.52; p = 0.66). Ischemia-driven target vessel revascularization occurred more frequently in the PCI group than in the CABG group (11.4% and 5.5%, respectively; HR: 2.11; 95% CI: 1.16 to 3.84; p = 0.012).
CONCLUSIONS: During 5 years of follow-up, our study did not show significant difference regarding the rate of MACCE between patients who underwent PCI with a sirolimus-eluting stent and those who underwent CABG. However, considering the limited power of our study, our results should be interpreted with caution. (Bypass Surgery Versus Angioplasty Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease [PRECOMBAT]; NCT00422968).
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  coronary artery bypass grafting; long-term outcome; percutaneous coronary intervention

Mesh:

Substances:

Year:  2015        PMID: 25787197     DOI: 10.1016/j.jacc.2015.03.033

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  76 in total

1.  Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials.

Authors:  Salvatore Cassese; Sebastian Kufner; Erion Xhepa; Robert A Byrne; Johanna Kreutzer; Tareq Ibrahim; Klaus Tiroch; Marco Valgimigli; Ralph Tölg; Massimiliano Fusaro; Heribert Schunkert; Karl-Ludwig Laugwitz; Julinda Mehilli; Adnan Kastrati
Journal:  Clin Res Cardiol       Date:  2015-12-22       Impact factor: 5.460

2.  Understanding Left Main Disease: Will the Right SYNTAX Help Us EXCEL in (PRE)COMBAT?

Authors:  Angela M Taylor; Michael Ragosta
Journal:  J Cardiovasc Transl Res       Date:  2015-06-02       Impact factor: 4.132

3.  Coronary artery disease. Drug-eluting stents or CABG?

Authors:  João H Duarte
Journal:  Nat Rev Cardiol       Date:  2015-03-31       Impact factor: 32.419

4.  Impact of left main coronary artery disease on long-term mortality in patients undergoing drug-eluting stent implantation.

Authors:  Se Hun Kang; Cheol Whan Lee; Seunghee Baek; Pil Hyung Lee; Jung-Min Ahn; Duk-Woo Park; Soo-Jin Kang; Seung-Whan Lee; Young-Hak Kim; Seong-Wook Park; Seung-Jung Park
Journal:  Clin Res Cardiol       Date:  2017-08-03       Impact factor: 5.460

5.  Optimal revascularization for left main coronary artery disease-coronary artery bypass grafting versus percutaneous coronary intervention.

Authors:  Ian C Bostock; Jock N McCullough; Alexander Iribarne
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

6.  Very long-term follow-up for left main coronary artery stenting: a missing piece of the jigsaw puzzle.

Authors:  Yalcin Velibey; Tolga Sinan Guvenc; Ahmet Taha Alper
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

7.  Stenting or bypass surgery for unprotected left main coronary artery disease-still a long rally to go.

Authors:  Tzu-Hsien Tsai; Cheng-I Cheng
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

8.  Pivotal contemporary trials of percutaneous coronary intervention vs. coronary artery bypass grafting: a surgical perspective.

Authors:  Janet M C Ngu; Louise Y Sun; Marc Ruel
Journal:  Ann Cardiothorac Surg       Date:  2018-07

9.  Percutaneous coronary intervention in left main disease: SYNTAX, PRECOMBAT, EXCEL and NOBLE-combined cardiology and cardiac surgery perspective.

Authors:  Duk-Woo Park; Jung-Min Ahn; Seung-Jung Park; David P Taggart
Journal:  Ann Cardiothorac Surg       Date:  2018-07

10.  Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Left Main Coronary Artery Stenosis: A Systematic Review and Meta-analysis.

Authors:  Daniele Giacoppo; Roisin Colleran; Salvatore Cassese; Antonio H Frangieh; Jens Wiebe; Michael Joner; Heribert Schunkert; Adnan Kastrati; Robert A Byrne
Journal:  JAMA Cardiol       Date:  2017-10-01       Impact factor: 14.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.